Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Xinxiang Tuoxin Pharmaceutical Co.Ltd. ¥12.27, price ¥24.16, upside -49.2%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Xinxiang Tuoxin Pharmaceutical Co.Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
59‑month range ¥19.99 – ¥209.98 · fair‑value band ¥8.78 – ¥15.68 · the ¥24.16 price screens above the ¥12.27 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Xinxiang Tuoxin Pharmaceutical Co.Ltd. in your weekly email
Every Wednesday you see whether Xinxiang Tuoxin Pharmaceutical Co.Ltd. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China.
Show more
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxiang, China.
Stock analysis
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) currently trades at ¥24.16, while our model-based Fair Value estimate is ¥12.27, implying the stock looks roughly 96.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: ¥8.78 (bear) to ¥15.68 (bull), the price of ¥24.16 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. reported revenue of 378M CNY in FY2025 versus 502M CNY in FY2021, a compound −6.8%/yr. Reported net income was −69.7M CNY in FY2025.
Key figures
Market cap 3.1B CNY (≈ $456M) · P/S ratio 7.41 · EPS (TTM) ¥−0.6000 · Dividend yield 1.1% · Net margin −18.4% · Return on equity −5.1% · Return on assets (EBIT) 7.6% · Operating margin −9.5%.
What moves the price
The share trades about 37% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −49%, 301089 screens richer than that median.
Fair Value models
Bear ¥8.78Fair Value ¥12.27Bull ¥15.68
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−10.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
28.6% (2020) → −12.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Xinxiang Tuoxin Pharmaceutical Co.Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 614 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside−49% · Below median
Profitability
Return on assets−3% · Bottom 25%
Net margin (TTM)−20% · Bottom 25%
Operating margin (TTM)−10% · Bottom 25%
Growth and dividend
Revenue growth−5% · Below median
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.31× · Cheapest 25%
P/S (TTM)1.22× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 12
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 25
HEALTH (low debt)100· sector 96
DIVIDEND (yield)23· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥12.27 versus a price of ¥24.16, about −49% upside (overvalued).
What is the fair value of 301089?
Our model-based fair value for Xinxiang Tuoxin Pharmaceutical Co.Ltd. is ¥12.27 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥24.16.
What is the quality score of 301089?
Xinxiang Tuoxin Pharmaceutical Co.Ltd. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
Our model-based price target is the fair value of ¥12.27 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario ¥8.78, optimistic scenario ¥15.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Xinxiang Tuoxin Pharmaceutical Co.Ltd. stock forecast for 2026?
Our models put fair value at ¥12.27, about −49% upside versus a price of ¥24.16 (overvalued). Cautious scenario ¥8.78, optimistic scenario ¥15.68. The calculation is refreshed regularly with new filings.
What is the revenue of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
Xinxiang Tuoxin Pharmaceutical Co.Ltd. reported trailing-twelve-month revenue of about 374M CNY (latest available figure, as of Sep 24, 2026).
Does Xinxiang Tuoxin Pharmaceutical Co.Ltd. pay a dividend?
Xinxiang Tuoxin Pharmaceutical Co.Ltd. currently shows a dividend yield of about 1.14% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xinxiang Tuoxin Pharmaceutical Co.Ltd. it is ¥12.27 per share (as of Sep 24, 2026), against a price of ¥24.16. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Xinxiang Tuoxin Pharmaceutical Co.Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 301089 trades above its calculated fair value: price ¥24.16, fair value ¥12.27, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301089?
No. The price is what the market pays today (¥24.16); the fair value is what the company's own numbers justify (¥12.27). For Xinxiang Tuoxin Pharmaceutical Co.Ltd. the two are ¥11.89 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xinxiang Tuoxin Pharmaceutical Co.Ltd. worth?
The market values Xinxiang Tuoxin Pharmaceutical Co.Ltd. at about 3.1B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥24.16; our models calculate a fair value of ¥12.27 per share.
What do the bullish and bearish scenarios say about 301089?
Our models span a range for Xinxiang Tuoxin Pharmaceutical Co.Ltd.: cautious scenario ¥8.78, base ¥12.27, optimistic ¥15.68 per share (as of Sep 24, 2026, price ¥24.16). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
Balance-sheet figures for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (as of Sep 24, 2026): return on equity −5.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 301089 from its 52-week high?
Xinxiang Tuoxin Pharmaceutical Co.Ltd. trades at ¥24.16, about 37% below its 52-week high of ¥38.45 and 15% above the low of ¥20.99 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥12.27 is for.
Which stocks are comparable to Xinxiang Tuoxin Pharmaceutical Co.Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xinxiang Tuoxin Pharmaceutical Co.Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price ¥24.16, calculated fair value ¥12.27 (−49%), Quality Score 41/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301089 calculated?
We run Xinxiang Tuoxin Pharmaceutical Co.Ltd. through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥12.27, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Xinxiang Tuoxin Pharmaceutical Co.Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The closing price on Sep 22, 2026 was ¥24.16. Our model-based fair value is ¥12.27, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xinxiang Tuoxin Pharmaceutical Co.Ltd. right now?
The price sits above even our optimistic bull case (¥15.68). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Xinxiang Tuoxin Pharmaceutical Co.Ltd.
How large is the market capitalisation of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The market capitalisation of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is 3.1B CNY (≈ $456M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The price-to-sales ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is 7.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
Earnings per share at Xinxiang Tuoxin Pharmaceutical Co.Ltd. are ¥−0.6000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The dividend yield of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The net margin of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is −18.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The return on equity (ROE) of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is −5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
On an EBIT basis the return on assets of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
The operating margin of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is −9.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089)?
Revenue at Xinxiang Tuoxin Pharmaceutical Co.Ltd. is growing −4.6% versus a year earlier (3y avg −21.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) generate?
The free cash flow of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is −70.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) carry?
The net debt of Xinxiang Tuoxin Pharmaceutical Co.Ltd. is 29.3M CNY (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Xinxiang Tuoxin Pharmaceutical Co.Ltd. in the live analysis
One click puts Xinxiang Tuoxin Pharmaceutical Co.Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
